Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis.
PRRT
Paraganglioma
Pheochromocytoma
Somatostatin Receptors
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
22
11
2023
accepted:
18
01
2024
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
aheadofprint
Résumé
Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumors and available systemic therapies are limited. To explore the role of peptide receptor radionuclide therapy (PRRT) with Yttrium-90 ( We retrospectively analyzed more than 1500 patients with histologically proven neuroendocrine tumors treated with Thirty (n = 30) patients were treated: 22 with PGLs and 8 with PCCs (12 M and 18 F, median age 47 [IQR: 35-60 years]). Eighteen patients (n = 18) had head and neck PGLs, 3 patients thoracic PGLs and 1 patient abdominal PGL. Sixteen patients (53%) had locally advanced and fourteen (47%) had metastatic disease. Twenty-seven (90%) patients had disease progression at baseline. Four (13%) patients were treated with PRRT with
Sections du résumé
BACKGROUND
BACKGROUND
Malignant pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare tumors and available systemic therapies are limited.
AIM
OBJECTIVE
To explore the role of peptide receptor radionuclide therapy (PRRT) with Yttrium-90 (
METHODS
METHODS
We retrospectively analyzed more than 1500 patients with histologically proven neuroendocrine tumors treated with
RESULTS
RESULTS
Thirty (n = 30) patients were treated: 22 with PGLs and 8 with PCCs (12 M and 18 F, median age 47 [IQR: 35-60 years]). Eighteen patients (n = 18) had head and neck PGLs, 3 patients thoracic PGLs and 1 patient abdominal PGL. Sixteen patients (53%) had locally advanced and fourteen (47%) had metastatic disease. Twenty-seven (90%) patients had disease progression at baseline. Four (13%) patients were treated with
CONCLUSION
CONCLUSIONS
PRRT with
Identifiants
pubmed: 38324106
doi: 10.1007/s12020-024-03707-5
pii: 10.1007/s12020-024-03707-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
F.A. Farrugia, A. Charalampopoulos, Pheochromocytoma. Endocr. Regul. 53(3), 191–212 (2019).
doi: 10.2478/enr-2019-0020
pubmed: 31517632
V.L. Martucci, K. Pacak, Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr. Probl. Cancer 38(1), 7–41 (2014).
doi: 10.1016/j.currproblcancer.2014.01.001
pubmed: 24636754
pmcid: 3992879
S. Jhawar, Y. Arakawa, S. Kumar, D. Varghese, Y.S. Kim, N. Roper, et al. New insights on the genetics of pheochromocytoma and paraganglioma and its clinical implications. Cancers (Basel). 14(3), 594 (2022).
A. Cascon, B. Calsina, M. Monteagudo, S. Mellid, A. Diaz-Talavera, M. Curras-Freixes, et al. Genetic bases of pheochromocytoma and paraganglioma. J. Mol. Endocrinol. 70(3), e220167 (2023).
M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. de la Fouchardiere, H.R. Haak, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(11), 1476–1490 (2020).
doi: 10.1016/j.annonc.2020.08.2099
pubmed: 32861807
M. Fassnacht, G. Assie, E. Baudin, G. Eisenhofer, C. Fouchardiere, H.R. Haak, et al., Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACANClinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annalsof Oncology volume]. Ann. Oncol. 31, 1476–1490 (2022).
doi: 10.1016/j.annonc.2020.08.2099
O. Hamidi, W.F. Young Jr., N.M. Iniguez-Ariza, N.E. Kittah, L. Gruber, C. Bancos et al. Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years. J. Clin. Endocrinol. Metab. 102(9), 3296–3305 (2017).
doi: 10.1210/jc.2017-00992
pubmed: 28605453
pmcid: 5587061
R. Garcia-Carbonero, F. Matute Teresa, E. Mercader-Cidoncha, M. Mitjavila-Casanovas, M. Robledo, I. Tena et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin. Transl. Oncol. 23(10), 1995–2019 (2021).
doi: 10.1007/s12094-021-02622-9
pubmed: 33959901
pmcid: 8390422
L.B. Mercado-Asis, K.I. Wolf, I. Jochmanova, D. Taieb, Pheochromocytoma: a genetic and diagnostic update. Endocr. Pract. 24(1), 78–90 (2018).
doi: 10.4158/EP-2017-0057
pubmed: 29144820
L.T. van Hulsteijn, N.D. Niemeijer, O.M. Dekkers, E.P. Corssmit, (131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. (Oxf.) 80(4), 487–501 (2014).
doi: 10.1111/cen.12341
pubmed: 24118038
G.D. Di Stasio, V. Cuccurullo, G.L. Cascini, C.M. Grana, Tailored molecular imaging of pheochromocytoma and paraganglioma: which tracer and when. Neuroendocrinology 112(10), 927–940 (2022).
doi: 10.1159/000522089
pubmed: 35051937
L. Bodei, G. Pepe, G. Paganelli, Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. Eur. Rev. Med Pharm. Sci. 14(4), 347–351 (2010).
D.J. Pinato, J.R. Black, R. Ramaswami, T.M. Tan, D. Adjogatse, R. Sharma, Peptide receptor radionuclide therapy for metastatic paragangliomas. Med Oncol. 33(5), 47 (2016).
doi: 10.1007/s12032-016-0737-9
pubmed: 27059363
J. Strosberg, G. El-Haddad, E. Wolin, A. Hendifar, J. Yao, B. Chasen et al. Phase 3 Trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N. Engl. J. Med 376(2), 125–135 (2017).
doi: 10.1056/NEJMoa1607427
pubmed: 28076709
pmcid: 5895095
M.H. Shah, W.S. Goldner, A.B. Benson, E. Bergsland, L.S. Blaszkowsky, P. Brock et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc Netw. 19(7), 839–868 (2021).
doi: 10.6004/jnccn.2021.0032
pubmed: 34340212
G. Kong, S. Grozinsky-Glasberg, M.S. Hofman, J. Callahan, A. Meirovitz, O. Maimon et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and pheochromocytoma. J. Clin. Endocrinol. Metab. 102(9), 3278–3287 (2017).
doi: 10.1210/jc.2017-00816
pubmed: 28605448
V. Ambrosini, J. Kunikowska, E. Baudin, L. Bodei, C. Bouvier, J. Capdevila et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur. J. Cancer 146, 56–73 (2021).
doi: 10.1016/j.ejca.2021.01.008
pubmed: 33588146
pmcid: 8903070
M.P. Yadav, S. Ballal, C. Bal, Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. EJNMMI Res. 9(1), 13 (2019).
doi: 10.1186/s13550-019-0484-y
pubmed: 30725219
pmcid: 6365580
L. Urso, A. Nieri, L. Uccelli, A. Castello, P. Artioli, C. Cittanti, M.C. Marzola, L. Florimonte, M. Castellani, S. Bissoli, F. Porto, A. Boschi, L. Evangelista, M. Bartolomei, Lutathera® orphans: state of the art and future application of radioligand therapy with 177Lu-DOTATATE. Pharmaceutics 15(4), 1110 (2023).
doi: 10.3390/pharmaceutics15041110
pubmed: 37111596
pmcid: 10142322
A.L. Marretta, A. Ottaiano, D. Iervolino, A. Bracigliano, O. Clemente, F. Di Gennaro, et al. Response to peptide receptor radionuclide therapy in pheocromocytomas and paragangliomas: a systematic review and meta-analysis. J. Clin. Med. 12(4), 1494 (2023).
S. Prado-Wohlwend, M.I. Del Olmo-Garcia, P. Bello-Arques, J.F. Merino-Torres, Response to targeted radionuclide therapy with [(131)I]MIBG AND [(177)Lu]Lu-DOTA-TATE according to adrenal vs. extra-adrenal primary location in metastatic paragangliomas and pheochromocytomas: a systematic review. Front Endocrinol. (Lausanne) 13, 957172 (2022)
doi: 10.3389/fendo.2022.957172
pubmed: 36339441
W.T. Zandee, R.A. Feelders, D.A. Smit Duijzentkunst, J. Hofland, R.M. Metselaar, R.A. Oldenburg et al. Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE. Eur. J. Endocrinol. 181(1), 45–53 (2019).
doi: 10.1530/EJE-18-0901
pubmed: 31067510
A.R. Vyakaranam, J. Crona, O. Norlen, D. Granberg, U. Garske-Roman, M. Sandstrom, et al. Favorable outcome in patients with pheochromocytoma and paraganglioma treated with (177)Lu-DOTATATE. Cancers (Basel). 11(7), 909 (2019).
A. Kolasinska-Cwikla, M. Peczkowska, J.B. Cwikla, I. Michalowska, J.M. Palucki, L. Bodei, et al. A clinical efficacy of PRRT in patients with advanced, nonresectable, paraganglioma-pheochromocytoma, related to SDHx gene mutation. J. Clin. Med. 8(7), 952 (2019).
S. Severi, A. Bongiovanni, M. Ferrara, S. Nicolini, F. Di Mauro, M. Sansovini et al. Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open 6(4), 100171 (2021).
doi: 10.1016/j.esmoop.2021.100171
pubmed: 34139487
pmcid: 8219772
L. Bodei, M. Kidd, G. Paganelli, C.M. Grana, I. Drozdov, M. Cremonesi et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur. J. Nucl. Med Mol. Imaging 42(1), 5–19 (2015).
doi: 10.1007/s00259-014-2893-5
pubmed: 25273832
M.P. Yadav, S. Ballal, R.K. Sahoo, C. Bal, Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. Eur. J. Nucl. Med Mol. Imaging 49(5), 1595–1606 (2022).
doi: 10.1007/s00259-021-05632-5
pubmed: 34837103